• Read more about Pfizer’s HYMPAVZI Receives Positive CHMP Opinion for Once-Weekly Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors

NEW YORK, March 27, 2026 –Pfizer Inc. (NYSE: PFE)announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for HYMPAVZI® (marstacimab) to expand the approved indication to include patients 12 years of age and older weighing at least 35 kg with hemophilia A (congenital factor VIII [FVIII] deficiency) with FVIII inhibitors, or hemophilia B (congenital factor IX [FIX] deficiency) with FIX inhibitors.

• Read more about The Pfizer Foundation Expands Breast Cancer Initiative to Kenya and Ethiopia with $10 Million in Grants

• Read more about ACIP COVID-19 Public Statement

NEW YORK and MAINZ, GERMANY, SEPTEMBER 19, 2025 — Over the past five years, Pfizer and BioNTech's COVID-19 vaccine efforts reflect a continuous commitment to address a public health challenge. The Pfizer and BioNTech COVID-19 vaccine, with over 5 billion doses distributed globally, has consistently demonstrated a favorable safety and efficacy profile. Randomized clinical trials, real-world effectiveness studies and global pharmacovigilance confirm the vaccine helps prevent COVID-19 related hospitalizations, severe illness, and death.

• Read more about Pfizer-BioNTech Statement to ACIP Meeting 19th September 2025

On behalf of our teams at Pfizer and BioNTech, thank you for the presentations today and the opportunity to address the committee.

COVID-19 has transitioned from a pandemic to an endemic disease. Even so, COVID-19 disease still hospitalizes hundreds of thousands of Americans and is responsible for the death of thousands every year.(1)

• Read more about Pfizer Reaffirms Safety and Efficacy of COVID-19 Vaccines

NEW YORK, Tuesday, September 16, 2025 – Pfizer Inc. (NYSE: PFE) today reaffirmed the safety and efficacy of the COVID-19 vaccine and posted resources supporting its impact on global health. These sources reflect the company’s commitment to transparency and ensure the accessibility of the data. The evidence has previously been shared with regulatory authorities and presented in scientific forums, as well as published in peer-reviewed publications.

• Read more about Pfizer Shares Available Analyses of Myocarditis and COVID-19 Vaccines

NEW YORK, Monday, September 15, 2025 – Pfizer Inc. (NYSE: PFE) today posted publicly available COVID-19 data from global analyses of myocarditis, further representing its dedication to transparency. The extensive and growing body of scientific evidence has also been presented in scientific forums and published in peer-reviewed publications, and Pfizer has posted these myocarditis data in Pfizer’s COVID-19 updates and research hub. It provides the following findings:

• Read more about Pfizer Upholds Commitment to Transparency and Shares Analysis of COVID-19 Vaccination in Pregnant Women

NEW YORK, Tuesday, September 9, 2025 – Pfizer Inc. (NYSE: PFE) today posted COVID-19 vaccine data in pregnant women, continuing to deliver on President Trump’s call for transparency of our findings in an open and accessible manner. A summary of clinical and real-world evidence published in Pfizer’s COVID-19 updates and research hub provides the following findings:

• Read more about Pfizer Responds to Success of Operation Warp Speed and Reaffirms Transparency of COVID Vaccine Data

NEW YORK, Wednesday, September 3, 2025 – Pfizer Inc. (NYSE: PFE) today reaffirmed its commitment to transparently and consistently disclosing its research findings regarding its COVID-19 vaccine and to maintaining the integrity of those ongoing studies for all those we serve. Dr. Albert Bourla, Chairman and CEO, made the following statement:

• Read more about Pfizer Provides Update on Phase 3 Inclacumab Study for the Treatment of People with Sickle Cell Disease

• Read more about Pfizer Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer

New York, June 13, 2025 – Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration’s (FDA) decision on the supplemental New Drug Application (sNDA) for TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) for men with metastatic castration-resistant prostate cancer (mCRPC).